The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PDSB | -70.43% | -58.76% | -16.22% | -89% |
| S&P | +16.9% | +95.99% | +14.39% | +140% |
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 0.0% |
| Market Cap | $60.79M | -43.4% |
| Market Cap / Employee | $2.53M | 0.0% |
| Employees | 24 | -4.0% |
| Net Income | -$9.43M | -13.3% |
| EBITDA | -$7.61M | 12.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $31.87M | -44.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.98M | -6.6% |
| Short Term Debt | $5.55M | -47.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -72.50% | -7.0% |
| Return On Invested Capital | -73.62% | -14.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.10M | -2.4% |
| Operating Free Cash Flow | -$9.10M | -2.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.54 | 2.73 | 2.38 | 2.70 | -6.48% |
| Price to Tangible Book Value | 4.54 | 2.73 | 2.38 | 2.70 | -6.48% |
| Enterprise Value to EBITDA | -11.37 | -5.68 | -2.99 | -6.27 | -26.69% |
| Return on Equity | -174.5% | -166.7% | -119.2% | -156.2% | 21.62% |
| Total Debt | $24.67M | $21.83M | $18.96M | $18.54M | -23.96% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
